Table 1. Clinical and pathological patient characteristics.
| Characteristics | MiRNA array cohort (n=16) | Validation cohort (n=24) | MiRNA signature testing cohort (n=54) | Plasma miRNA cohort (n=20)* |
|---|---|---|---|---|
| Gender | ||||
| Male | 6 | 14 | 28 | 12 |
| Female | 10 | 10 | 26 | 8 |
| Age, median (range) | 62 (44-84) years | 64.5 (44-77) years | 66 (38-82) years | 64 (45-83) years |
| Number of evaluated LN | ||||
| Median (range) | 12 (4-23) | 20 (18-25) | 16 (7- 28) | 12 (1-24) |
| Number of affected LN | ||||
| 0 | 8 | 13 | 19 | 10 |
| 1-3 | 6 | 2 | 22 | 8 |
| 4-9 | 2 | 9 | 13 | 2 |
| Differentiation | ||||
| Well | 1 | 0 | 6 | 6 |
| Moderate | 10 | 12 | 11 | 9 |
| moderate to poor | 0 | 5 | 9 | 2 |
| Poor | 4 | 7 | 22 | 0 |
| Unknown | 1 | 0 | 6 | 3 |
| Lymphovascular invasion | ||||
| Yes | 4 | 6 | 25 | 4 |
| No | 8 | 6 | 16 | 11 |
| n/a | 4 | 12 | 13 | 5 |
| Perineural invasion | ||||
| Yes | 9 | 17 | 40 | 14 |
| No | 2 | 3 | 5 | 4 |
| n/a | 5 | 4 | 9 | 2 |
| Tumor size, median (range) | 3 (1.2-8.5) cm | 3 (2.1-6) cm | 3.6 (0.4-5.8) | 3 (1.5-4.5) cm |
* The plasma miRNA cohort includes 20 PDAC patients and 10 normal controls; clinical and pathological characteristics of this cohort represent the sub group of PDAC patients.